LifeSpeak Inc. and Eyesafe Partner to Promote Eye Health During Healthy Vision Month
Expert-led education, savings on Eyesafe® Blue Light Glasses, and integrated wellness solutions aim to address the health effects of rising screen time
MINNEAPOLIS, May 20, 2025 /PRNewswire/ — LifeSpeak Inc., the leading provider of mental, physical, and family wellbeing solutions for employers, health plans, and other organizations, and Eyesafe, a global leader in blue light and screen time solutions, today announced a strategic partnership to address the rising impact of blue light exposure on eye health, sleep, and overall wellness.
As screen time now averages more than 11 hours per day,¹ blue light from digital devices has become a growing concern among doctors, employers, and individuals. Many people experience symptoms such as digital eye strain, headaches, and disrupted sleep cycles due to prolonged screen use.²
The collaboration between LifeSpeak Inc. and Eyesafe, launching during Healthy Vision Month, aims to educate individuals about the concerns of excessive screen time, while providing product solutions to help reduce blue light exposure and enhance overall wellbeing.
Key highlights of the partnership include:
Expert-led educational content: A series of expert-led videos discussing the concerns for blue light exposure in both children and adults, available through LifeSpeak Inc.'s robust platform of wellness resources.
Exclusive member benefit: A $25 voucher for LifeSpeak members to use towards Eyesafe® Eyewear, featuring advanced BluTech lens technology designed to filter out blue light to reduce strain and enhance sleep.
Comprehensive wellness approach: Integration of blue light, vision, and sleep health resources into LifeSpeak Holistic Wellness, which combines support for mental health, fitness, nutrition, mindfulness, and more to deliver in a simplified approach that advances health outcomes for every individual's unique wellness journey.
Michael Held, founder and CEO of LifeSpeak Inc. states, 'Our partnership with Eyesafe aligns perfectly with LifeSpeak Inc.'s mission to support all facets of wellness so that wellbeing is attainable for everyone. By integrating the often-overlooked aspect of eye health into our expert content, we're delivering on this mission and while improving the quality of life for individuals and health outcomes for employers and health plans.'
Justin Barrett, CEO of Eyesafe, added, 'We're thrilled to partner with LifeSpeak Inc. to bring Eyesafe Eyewear to a wider audience. Our blue light glasses are developed with doctors and backed by research showing positive user benefits, including increased melatonin and reduced eye strain.3,4 This collaboration represents a significant step in making blue light protection a priority in the broader context of wellness.'
The partnership comes at a crucial time, as May is recognized as Healthy Vision Month. The National Eye Institute recommends regular eye exams, wearing sunglasses when outdoors, and being aware of your family eye health history as key steps in maintaining healthy vision.
Additionally, Dr. Ralph Chu, Founder of Chu Vision Institute and member of the Eyesafe Vision Health Advisory Board, recommends reducing exposure to blue light to minimize visual discomfort and sleep disruption, while following the 20/20/20 rule: every 20 minutes, look away from your screen and focus on something at least 20 feet away for 20 seconds. This gives your eyes a break, which can reduce eye strain and dry eye conditions.
LifeSpeak Inc. and Eyesafe's joint initiative will be available to employers, health plans, and organizations that contract with LifeSpeak Inc. for wellbeing solutions, ultimately benefiting millions of individuals worldwide.
For more information, visit lifespeak.com.
All trademarks are the property of their respective owners. This press release does not provide medical advice, and its products are not intended to diagnose, treat, cure or prevent any disease or medical condition. Please consult your physician or other qualified health care provider with any questions you may have about your health. Visit https://eyesafe.com/disclaimer for more information.
Eyesafe estimate based on Nielsen Total Audience Reports, 2018-2023, US. Some amounts of simultaneous usage may occur across devices.
'Computer Vision Syndrome.' Available at https://www.aoa.org/healthy-eyes/eye-and-vision-conditions/computer-vision-syndrome.
BluTech study, published by Van, et al. 'Blue Light-Blocking Glasses May Help With Sleep, Cognition.' Nova Southeastern University College of Optometry, presented at the American Academy of Optometry (AAOpt) October 14, 2017.
BluTech Wearer Study of over 2,000 patients, 2023.
About LifeSpeak Inc. LifeSpeak Inc. is the leading provider of mental, physical, and family wellbeing solutions for employers, health plans, and organizations worldwide. Our innovative suite of digital solutions delivers best-in-class content and human expertise at scale, supporting individuals at every stage of their wellbeing journey. Through our comprehensive portfolio – featuring LifeSpeak Holistic Wellness, ALAViDA Substance Use, and Torchlight Parenting & Caregiving – we enrich the lives of over 14 million individuals and their families across every pillar of wellbeing. With 24/7 access to our constantly expanding library of expert-led resources, we make it simple for members to find trusted support whenever and wherever they need it. For organizations, LifeSpeak drives stronger engagement and healthier, higher-performing teams. For health plans, we enable members to take a proactive approach to their wellbeing, improving population health while reducing high-cost claims through preventative care. Built on two decades of excellence, LifeSpeak Inc. continues to lead the wellbeing revolution worldwide, transforming how people access and experience wellbeing support – anytime, anywhere. Learn more at www.LifeSpeak.com or follow us on LinkedIn.
About EyesafeEyesafe Inc. is the world leader in blue light management, including display technology, standards, certification, and eyewear solutions. With an expansive portfolio of intellectual property, the company employs a world-class team of eye doctors, engineers, and scientists with expertise in electronics, display materials, light management, optometry, and ophthalmology. The Eyesafe brand is trusted by millions of consumers and integrated into digital devices from Dell, HP, Lenovo, LG, ZAGG, and more. Recognized by Inc. 5000 as one of the fastest-growing private companies in America, and by the Minneapolis/St. Paul Business Journal as the #1 Fastest Growing Company in Minnesota in 2022, Eyesafe is redefining digital wellness. For more information, visit www.eyesafe.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
3 days ago
- Malaysian Reserve
Wild About Sprouts® Celebrates World Food Safety Day with Breakthrough Cold-Grown® Technology That Redefines Safety and Nutrition
SCOTTSDALE, Ariz., June 6, 2025 /PRNewswire/ — In honor of World Food Safety Day June 7, Wild About Sprouts® is shining a spotlight on its revolutionary Cold-Grown® process—an all-natural, patented innovation that has redefined food safety standards in the sprouting industry. With over 25 million containers sold pathogen-free and never part of any recall over its 8+ years, Wild About Sprouts is the only national sprout brand in the U.S., now proudly available in over 7,000 grocery stores across the country. Sprouts are among the most powerful, studied, and nutrient-dense superfoods on the planet. Yet for decades, their potential has been limited by persistent food safety concerns. Wild About Sprouts has solved that problem. Its Cold-Grown® process eliminates the risk of dangerous pathogens without the use of pesticides, herbicides, or chemical intervention, and uses 95% less water than traditional growing systems—making it one of the most sustainable solutions in fresh food today. 'At Wild About Sprouts, food safety isn't a feature—it's the foundation,' said Barry Didato, CEO of Rä Foods, parent company of Wild About Sprouts. 'Our patented Cold-Grown® method is changing the way America eats—combining breakthrough safety with unmatched nutrition, delivering sprouts that contain up to 100 times more antioxidants, vitamins, and minerals than fully grown vegetables. Backed by over 2,000 studies, sprouts—especially broccoli sprouts—are rich in sulforaphane, a proven compound that supports the body's natural detox pathways, helps fight cancer, reduces inflammation, and shows promise in managing conditions like autism, diabetes, and neurodegenerative disease.' Observed every year on June 7, World Food Safety Day highlights the importance of safe, accessible food for all. Wild About Sprouts is proud to lead this charge—proving that innovation can make clean, nutrient-packed, fresh foods not just possible, but scalable. 'Wild About Sprouts has not only innovated with its Cold-Grown® technology—they've demonstrated an uncompromising commitment to public health,' said Dr. Darin Detwiler, Food Safety Advocate, Professor and Author of Food Safety: Past, Present, and Predictions. 'In an era when consumers demand both transparency and accountability, this company offers a clear model of how science and responsibility can align to create safer, more sustainable food systems. As we recognize World Food Safety Day, this kind of leadership is precisely what our food system needs to move from reaction to prevention.' Whether tossed in a salad, layered on a sandwich, or blended into smoothies, Wild About Sprouts products offer an easy and delicious way to boost everyday nutrition—safely. For more information, visit or follow us on Instagram at @wild_about_sprouts. Wild About Sprouts is available at major retailers including Kroger, Walmart, Whole Foods Market, Sprouts Farmers Market, Albertsons, and many more. About Wild About Sprouts®Founded in 2016 and based in Scottsdale, Arizona, Wild About Sprouts is transforming the sprout industry with its science-backed, Cold-Grown® technology. As part of Rä Foods, a family office dedicated to better-for-you innovations, Wild About Sprouts is on a mission to deliver safe, delicious, nutrient-dense foods that Make America Healthy Again—one sprout at a time.
BusinessToday
5 days ago
- BusinessToday
No Wires, No Limits: A Bold Leap in Cardiac Tech
Institut Jantung Negara (IJN) has made history with a medical first for Southeast Asia. The team successfully implanted the Abbott AVEIR™ DR, the world's first dual-chamber leadless pacemaker. Approved by the US Food and Drug Administration (FDA) in 2023, this device is a game-changer for individuals with heart rhythm disorders. 'This groundbreaking dual-chamber leadless pacemaker will revolutionise care for our patients and significantly expand the number of people we can help,' said Dr Azlan, Senior Consultant Cardiologist and Clinical Director of Interventional Electrophysiology and Implantable Devices at IJN. 'By eliminating traditional wires (leads) and surgical pockets, the system reduces common complications such as infections, lead dislodgement, and vessel blockage.' Designed for individuals with bradycardia (a slower-than-normal heart rate), AVEIR™ DR represents a significant leap in cardiac pacing. Unlike traditional pacemakers that rely on wires and are implanted under the skin, this system uses two tiny devices (each about one-tenth the size of a conventional pacemaker) implanted directly into the heart's right atrium and ventricle. At the core of this advancement is Abbott's proprietary i2i™ (implant-to-implant) communication technology. This system uses high-frequency pulses conducted through the body's blood flow to synchronise the two pacemakers in real-time. It not only provides beat-to-beat coordination but also conserves battery life far more efficiently than Bluetooth® or radio frequency-based systems. 'This technology opens up new possibilities for patients with abnormal heart rhythms,' added Dr Azlan. 'It also allows real-time pacing analysis during implantation, enabling precise positioning and reducing procedural risks.' At IJN, innovation is not just about adopting the latest medical devices—it's about improving patient outcomes. The successful use of the AVEIR™ DR system is a significant step forward for heart care in the region and further cements IJN's standing as a leader in cardiovascular medicine. Cardiovascular disease continues to pose a serious challenge in Malaysia and across Southeast Asia. IJN's Chief Executive Officer, Prof. Datuk Sri Dr Mohamed Ezani Md Taib, emphasised the importance of early diagnosis, public awareness, and the integration of advanced medical solutions to achieve better patient outcomes. Addressing media questions during a press conference, Dr Azlan addressed questions from the media about the long-term outcomes and potential limitations of the device. He noted that, based on over a decade of experience, the complication rate for leadless pacemakers remains very low—less than 1% in the short term and only slightly higher over the long term. The process of replacing the device when the battery is depleted is also simpler and safer, as there are no leads to remove. As stated, the device is specifically intended for patients with confirmed slow or irregular heart rhythms, typically diagnosed through ECG or other monitoring tools. While pacemakers are not suitable for all heart rhythm disorders, IJN's team is committed to training doctors from across Malaysia and the region to expand access to this life-changing technology. Plans are also underway to collaborate with manufacturers on future innovations tailored to specific patient needs. As with any new medical technology, cost remains a consideration. IJN is working to structure pricing that makes the device accessible to both public and private patients. The hospital's model of using private-sector revenue to subsidise public care will also help ensure broader access as the technology becomes more widely adopted. As the world's first and only dual-chamber leadless pacemaker, the AVEIR™ DR represents a significant advancement in minimally invasive heart care. Its wire-free design reduces risks, enables quicker recovery, and allows for future upgrades—reflecting Abbott's vision to empower patients to live fuller, healthier lives. Related
Malaysian Reserve
5 days ago
- Malaysian Reserve
Lotus Therapeutics Appoints Leslie Felix as Chief Growth Officer
Industry veteran to drive strategic expansion and innovation in complex generics BOCA RATON, Fla. , June 4, 2025 /PRNewswire/ — Lotus Therapeutics, the generic division of Speranza Therapeutics, proudly announces the appointment of Leslie Felix as Chief Growth Officer. With over 25 years of executive experience in the pharmaceutical sector, Felix brings a proven track record in the generics market, poised to steer Lotus Therapeutics through its next phase of growth and innovation. Established in 2024, Lotus Therapeutics is committed to revolutionizing access to life-changing medications by focusing on the development of complex and unique generic formulations. The company's mission centers on addressing unmet medical needs through innovative therapies, ensuring that advancements are accessible to those who need them most. Felix has successfully led P&L operations exceeding $300 million and has held key senior positions at leading pharmaceutical companies, where his go-to-market strategies solidified their leadership in the generics space. In 2020, he founded the Authorized Generics Coalition, reinforcing his dedication to industry advancement and patient access. 'Leslie's depth of expertise and forward-thinking approach are exactly what Lotus Therapeutics needs as we enter a pivotal phase of expansion,' said Sal Rafanelli, CEO of Lotus Therapeutics. 'We are excited to welcome him to our leadership team and look forward to the impact he will make in driving our strategic growth initiatives.' As Chief Growth Officer, Felix will oversee strategic partnerships and market development efforts, positioning Lotus Therapeutics for long-term success. His leadership is expected to enhance the company's capabilities in managing post-Loss of Exclusivity (LOE) assets and expanding its portfolio of complex generics. Lotus Therapeutics' foundation is built upon a legacy of innovation, with its executive team having previously founded BioMatrix®, a leader in specialty infusion services, and Speranza Therapeutics, known for launching ST Genesis®. This heritage underscores the company's commitment to delivering affordable, high-quality therapies that make a meaningful impact on patient lives For more information about Lotus Therapeutics and its mission to transform patient care with innovative generics, visit Media Contact: Lauren Saccone, lsaccone@
